Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Mar 2010

Kiyotani Kazuma, Mushiroda Taisei, Imamura Chiyo K, Hosono Naoya, Tsunoda Tatsuhiko, Kubo Michiaki, Tanigawara Yusuke, Flockhart David A, Desta Zeruesenay, Skaar Todd C, Aki Fuminori, Hirata Koichi, Takatsuka Yuichi, Okazaki Minoru, Ohsumi Shozo, Yamakawa Takashi, Sasa Mitsunori, Nakamura Yusuke, Zembutsu Hitoshi

Abstract excerpt

PURPOSE: The clinical efficacy of tamoxifen is suspected to be influenced by the activity of drug-metabolizing enzymes and transporters involved in the formation, metabolism, and elimination of its active forms. We investigated relationships of polymorphisms in transporter genes and CYP2D6 to cli...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to ATP-Binding Cassette Transporters

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Cytochrome P-450 CYP2D6

Share to Drug Resistance, Neoplasm

Share to Multidrug Resistance-Associated Protein 2

Share to Survival Analysis

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 20124171
DOI: 10.1200/JCO.2009.25.7246
PMCID: PMC4872305

Genes

ABCC2
ABCB1
ABCG2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-20124171-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.PMID 20124171Read ↗

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.Semantic proximity Read ↗

The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1.Semantic proximity Read ↗

CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.Semantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.Semantic proximity Read ↗

Effect of CYP2D6 polymorphisms on breast cancer recurrence.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.Semantic proximity Read ↗

The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.Semantic proximity Read ↗

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.Semantic proximity Read ↗

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.Semantic proximity Read ↗

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.